Jia Yin-Zhao, Liu Jing, Wang Geng-Qiao, Song Zi-Fang
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Key Laboratory of Coal Science and Technology of Ministry of Education, College of Chemistry and Chemical Engineering, Taiyuan University of Technology, Taiyuan, China.
Front Oncol. 2022 Mar 9;12:830420. doi: 10.3389/fonc.2022.830420. eCollection 2022.
Disorders of miR-484 expression are observed in cancer, different diseases or pathological states. There is accumulating evidence that miR-484 plays an essential role in the development as well as the regression of different diseases, and miR-484 has been reported as a key regulator of common cancer and non-cancer diseases. The miR-484 targets that have effects on inflammation, apoptosis and mitochondrial function include SMAD7, Fis1, YAP1 and BCL2L13. For cancer, identified targets include VEGFB, VEGFR2, MAP2, MMP14, HNF1A, TUSC5 and KLF12. The effects of miR-484 on these targets have been documented separately. Moreover, miR-484 is typically described as an oncosuppressor, but this claim is simplistic and one-sided. This review will combine relevant basic and clinical studies to find that miR-484 promotes tumorigenesis and metastasis in liver, prostate and lung tissues. It will provide a basis for the possible mechanisms of miR-484 in early tumor diagnosis, prognosis determination, disease assessment, and as a potential therapeutic target for tumors.
在癌症、不同疾病或病理状态中均观察到miR - 484表达紊乱。越来越多的证据表明，miR - 484在不同疾病的发生发展以及消退过程中发挥着重要作用，并且miR - 484已被报道为常见癌症和非癌症疾病的关键调节因子。对炎症、凋亡和线粒体功能有影响的miR - 484靶标包括SMAD7、Fis1、YAP1和BCL2L13。对于癌症，已确定的靶标包括VEGFB、VEGFR2、MAP2、MMP14、HNF1A、TUSC5和KLF12。miR - 484对这些靶标的影响已分别有文献记载。此外，miR - 484通常被描述为一种肿瘤抑制因子，但这种说法过于简单和片面。本综述将结合相关基础和临床研究发现，miR - 484在肝、前列腺和肺组织中促进肿瘤发生和转移。这将为miR - 484在早期肿瘤诊断、预后判定、疾病评估以及作为肿瘤潜在治疗靶点的可能机制提供依据。
